MF-300 / Epirium Bio - LARVOL DELTA

Inhibiting 15-PGDH restores redox homeostasis and confers neuroprotection in Parkinson's disease. (PubMed, Redox Biol) - "Mechanistically, in vitro exposure of BV2 microglia to LPS recapitulates induction of Lcn2, Cybb/N OX2 and superoxide, and all three of these effects are reversed by co-treating with prostaglandin E2 (PGE2), the prototypical degradation substrate of 15-PGDH. With a 15-PGDH inhibitor (MF-300) currently in human clinical trials for peripheral indications, these findings have translational relevance for PD."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease • IL1B • LCN2

Single and Multiple Ascending Dosing Administration of MF-300 in Healthy Participants (clinicaltrials.gov) - P1 | N=100 | Completed | Sponsor: Epirium Bio Inc.

New P1 trial

Epirium Bio Presenting New Preclinical Data on its 15-PGDH Inhibitor Program in Inflammatory Bowel Disease at Digestive Disease Week 2026 (Yahoo Finance) - "All doses of MF-300 significantly improved endoscopic measures of colitis severity, matching the response observed with the anti-p40 antibody positive control, a class of biologics used clinically in IBD that targets IL-12/23 signaling; All doses of MF-1305 improved DAI scores, comparable to the cyclosporine positive control, an established immunosuppressant used in IBD. MF-1305 also reduced inflammatory cytokines and improved histology scores, even exceeding the effects of cyclosporine in some endpoints."

Preclinical • Ulcerative Colitis